指标,指标类型,治疗组例数,治疗组变化均值,治疗组变化SD,对照组例数,对照组变化均值,对照组变化SD,组间差异,t检验P值,Mann-Whitney P值,Cohen's d,统计学差异,临床意义,排除双正常后_治疗组N,排除双正常后_对照组N,排除双正常后_P值,敏感性分析注释
ALT,主要,140,0.28428571428571425,11.52324064773854,141,-0.6808510638297872,10.832041852720481,0.9651367781155015,0.4701193006141666,0.808364208274471,0.08630405688207797,否,对照组更优或无差异,22,28,0.4051130200421078,排除118+113例双正常患者
AST,主要,140,0.6199285714285714,8.46646388914688,141,0.19148936170212766,6.185137593592543,0.4284392097264437,0.6287448581415862,0.6293600371852617,0.057787298137963634,否,对照组更优或无差异,24,15,0.7501954939843161,排除116+126例双正常患者
GGT,次要,140,2.914285714285714,23.02875453552251,141,-1.6382978723404256,18.86579542669926,4.55258358662614,0.07110133887534205,0.021105564531631264,0.2162702677537777,否,对照组更优或无差异,45,35,0.28751421779750963,排除95+106例双正常患者
ALP,次要,142,-1.6143911439114391,15.7654362029941,141,-0.8652482269503546,22.16149165239948,-0.7491429169610845,0.743586386376459,0.6883431411979657,-0.0389544910565607,否,治疗组更优,32,26,0.5945290811454594,排除110+115例双正常患者
白蛋白,次要,143,-0.07748251748251753,2.3546536088456747,141,1.1070921985815603,5.174948521346039,-1.1845747160640778,0.014099917430231285,0.3397365189942645,-0.29465352693186636,是,对照组更优或无差异,3,8,0.013580159650113709,排除140+133例双正常患者
胆红素,次要,140,0.7697857142857144,5.506750006782994,141,2.246808510638298,8.307041360810281,-1.4770227963525837,0.08003100720643887,0.0353051652492511,-0.20958456013648064,否,治疗组更优,78,80,0.35036298220341044,排除62+61例双正常患者
